What Oxford StemTech does

Oxford StemTech is a privately held UK biotechnology company founded in 2020 and headquartered at The Oxford Science Park in Oxford. The company is built around its proprietary ReproPlex™ platform for large-scale induced Pluripotent Stem Cell (iPSC) reprogramming, which it markets as achieving 98% efficiency using non-integrating methods and capable of processing 100+ donors in 3-4 months. The founders — Prof. Zameel Cader (Co-Founder and Director), Dr. Satyan Chintawar (Co-Founder and COO), and Dr. Galbha Duggal (Co-Founder and CSO) — are University of Oxford-affiliated experts in stem cell biology, neuroscience, and neurology, and the company's scientific positioning leans heavily on this academic credibility.

The service portfolio covers the end-to-end iPSC workflow: PBMC isolation, ReproPlex™ reprogramming, comprehensive quality control (SNP karyotyping, pluripotency markers, mycoplasma testing, STR authentication, trilineage differentiation — GLP-compliant with full documentation), differentiation into neural and other lineages, CRISPR genome engineering, an iPSC repository of disease-specific lines (autism, bipolar disorder, diabetes, migraine, pain channelopathies, Alzheimer's, Parkinson's, and healthy controls), and a bespoke drug discovery platform focused on neurological disorders and pain established in 2022. Advanced offerings include cerebral organoids and assembloids (scaled in 2025), proprietary CGRP releasing peptidergic nociceptor models, and multi-electrode array (MEA) assays for phenotypic and target-based screening.

Commercially, Oxford StemTech operates a fee-for-service, quote-based professional services model with direct B2B engagement targeting research institutions, pharmaceutical companies, and biotechnology startups. GTM is consultative and partnership-driven, with all pricing bespoke and not publicly disclosed, no minimum project size, and global service scope via direct sales (no resellers). Revenue is not publicly disclosed, no venture capital funding rounds have been announced, and the company has received non-dilutive UK government support in the form of an Innovate UK Biomedical Catalyst grant and an MRC Node grant in 2024.

Name

Oxford StemTech

Legal name

Oxford StemTech

Website

https://oxfordstemtech.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Oxford StemTech is a UK-based biotechnology company that provides fee-for-service iPSC reprogramming, differentiation, quality control, CRISPR editing, and neurological drug discovery services to academic researchers, pharmaceutical firms, and biotech startups using its proprietary ReproPlex™ platform.

Ownership category

akta.pro rank

Product category

Stem Cell Research Services (iPSC Contract Research)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• IPSC reprogramming services
• Stem cell biology services
• Drug discovery services
• CRISPR genome engineering
• Cell-based assay services

Headquarters

HQ city

Upper Heyford

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. iPSC Reprogramming Services: Fee-for-service reprogramming of patient donor samples into iPSCs using the ReproPlex™ platform. Pricing based on sample type and project scale. Delivered within 3-4 months for large-scale projects.
2. Bespoke Drug Discovery Services: Collaborative, partnership-driven drug discovery services for neurological disorders. Includes custom iPSC-derived neurons and glia, disease modeling (monolayer, organoid, assembloids), phenotypic and target-based screening, and MEA assays. Engagements range from target validation through lead optimisation.
3. iPSC Quality Control Services: Quality control testing for iPSC lines including Bespoke QC, Standard QC, and Complete QC packages. Provides comprehensive testing ensuring pluripotent nature and genomic stability with full documentation.
4. iPSC Differentiation Services: Differentiation services transforming pluripotent cells into specialised cell types including neural lineage (cortical, dopaminergic, motor, sensory, GABAergic, glutamatergic neurons; astrocytes, microglia, oligodendrocytes), macrophages, endothelial cells, pericytes, and smooth muscle cells.
5. PBMC Isolation Service: Standardised peripheral blood mononuclear cell isolation delivering high-quality, high-purity cells for downstream research applications including iPSC reprogramming. Successful isolation within 48 hours of blood withdrawal.
6. CRISPR Genome Engineering Services: Precision CRISPR genome editing in human iPSCs including gene knockout and isogenic controls, point mutation introduction or correction, reporter cell line generation, large insertions and deletions, regulatory DNA modifications, with comprehensive off-target and QC analysis.
7. iPSC Repository: Access to characterised iPSC lines from repository for accelerated research. Collection includes lines from autism, bipolar disorder, diabetes, migraine, pain channelopathies, monogenic and sporadic Alzheimer's disease, monogenic and sporadic Parkinson's disease, and healthy controls.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Oxford StemTech provides fee-for-service induced pluripotent stem cell (iPSC) reprogramming, differentiation, quality control, CRISPR genome engineering, PBMC isolation, and bespoke neurological drug discovery support using its proprietary ReproPlex™ platform, cerebral organoids, assembloids, and multi-electrode array assays. The company sells these services directly to research institutions, pharmaceutical companies, and biotechnology startups on a project-quoted basis.

Product overview

Oxford StemTech provides a comprehensive, end-to-end suite of iPSC-based services built around their proprietary ReproPlex™ platform. The portfolio spans the entire iPSC workflow: PBMC isolation feeds into ReproPlex™ reprogramming, which is followed by iPSC Quality Control and iPSC Differentiation services. The platform is complemented by CRISPR Genome Engineering for gene editing, an iPSC Repository of pre-characterized disease-specific lines, and Bespoke Drug Discovery services for neurological disorders utilizing 2D monolayer, 3D organoid, and assembloid models.

Differentiator

Problem solved

Functional benefit

Brands

• ReproPlex™: Standardized iPSC reprogramming and characterization platform for generating high-quality induced pluripotent stem cells for research and drug discovery.

Products and services

• ReproPlex™ iPSC Reprogramming Proprietary, large-scale induced pluripotent stem cell reprogramming service accepting blood (PBMCs, T cells, monocytes), skin biopsies (dermal fibroblasts), and other samples (keratinocytes, brain and intestinal fibroblasts), with reported 98% efficiency and 3–4 month delivery for 100+ donor projects. It is sold to research institutions, pharmaceutical companies, and biotechs needing scalable, high-quality iPSC generation.
• Bespoke Drug Discovery Custom, partnership-driven drug discovery engagement for neurological and pain disorders, spanning target validation through lead optimisation and using iPSC-derived neurons and glia, monolayer and 3D organoid/assembloid disease models, phenotypic and target-based screening, and multi-electrode array assays. It is delivered to pharmaceutical and biotechnology partners seeking human-relevant cell models for CNS drug discovery.
• iPSC Quality Control Comprehensive quality control testing services for iPSC lines covering SNP karyotyping and copy number analysis, pluripotency marker assessment (OCT4, SOX2, NANOG, TRA-1-60, SSEA-4), mycoplasma testing, freeze-thaw viability, STR authentication, and trilineage differentiation, offered in Bespoke, Standard, and Complete QC packages with GLP-compliant documentation. It is sold to researchers and pharma partners requiring publication-grade, traceable cell lines.
• iPSC Differentiation Expert differentiation service transforming iPSCs into specialised cell types, including neural lineages (cortical, dopaminergic, motor, sensory, GABAergic, and glutamatergic neurons; astrocytes, microglia, oligodendrocytes), macrophages, endothelial cells, pericytes, and smooth muscle cells, with cerebral organoids and assembloid 3D brain models. It is sold to researchers and pharma partners needing disease-relevant human cell models.
• PBMC Isolation Service Standardised peripheral blood mononuclear cell (PBMC) isolation delivering high-purity, high-viability cells within 48 hours of blood withdrawal for use in iPSC reprogramming and downstream research applications. It is sold to laboratories needing reliable input material for stem cell workflows.
• CRISPR Genome Engineering Precision CRISPR gene editing service in human iPSCs covering gene knockouts and isogenic controls, point mutation introduction or correction, reporter cell line generation, large insertions and deletions, and regulatory DNA modifications, with comprehensive off-target and quality control analysis. It is sold to biotech, pharma, and academic partners for disease modelling, target validation, and precision medicine research.
• iPSC Repository Access to a collection of characterised iPSC lines from autism, bipolar disorder, diabetes, migraine, pain channelopathies, monogenic and sporadic Alzheimer's and Parkinson's disease, and healthy controls, enabling accelerated research timelines through off-the-shelf patient-specific lines. It is sold to academic and industry researchers needing ready-to-use, disease-specific iPSC lines.

Quantifiable outcome

• 98% reprogramming efficiency with non-integrating methods
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators7 records

Recent moves11 records

Expansion highlights5 records

Broad incumbents

• Cellular Dynamics International (Fujifilm CDI): Acquired by Fujifilm in 2015, CDI is a leading commercial iPSC provider offering iPSC-derived cell lines and services across multiple tissue types. Directly comparable to Oxford StemTech's reprogramming and differentiation services, but with substantially greater scale and capital backing.
• ReproCELL (now REPROCELL): Established Japanese-headquartered provider of iPSC services, reagents, and drug discovery offerings. Comparable iPSC reprogramming and disease modeling services, with a more global footprint and broader product catalog than Oxford StemTech.
• Thermo Fisher Scientific (iPSC services): Through its Cell Therapy & iPSC services, Thermo Fisher offers large-scale iPSC reprogramming, differentiation, and characterization services globally. Indirect competitor in the same iPSC service category but as part of a much broader life-sciences portfolio.
• Lonza (Cell & Gene Services): Global CDMO offering cell therapy and iPSC-related services to pharma and biotech. Comparable at the high end of large-scale iPSC manufacturing and differentiation, but with vastly greater scale, regulatory depth, and pharma relationships.

Direct peers

• Axol Bioscience: UK-based provider of iPSC-derived cell types and custom iPSC services for neuroscience and drug discovery. Closely comparable in therapeutic focus (neuroscience) and service offering (iPSC-derived neurons, glia, custom reprogramming), making it Oxford StemTech's most direct competitor.
• Newcells Biotech: UK-based contract research organization specializing in iPSC-derived cell models and assay services for drug discovery, with strong focus on ophthalmology, kidney, and CNS models. Direct peer in geography, business model (CRO services), and iPSC disease modeling.
• BrainXell: Specializes in iPSC-derived neural cells and neurological disease modeling services, closely aligned with Oxford StemTech's neuroscience/pain focus. Both offer custom neuronal differentiation and drug screening assays for CNS research.

Emerging players

• Bit Bio: UK-based synthetic biology company providing iPSC-derived human cells at scale for research and drug discovery using proprietary transcription factor-based reprogramming. Comparable in iPSC focus and UK base, but with stronger venture funding and broader cell-type portfolio.
• Cedars-Sinai iPSC Core / FUJIFILM Cellular Dynamics: Academic and commercial iPSC cores provide reprogramming, banking, and differentiation services for researchers. Comparable as alternative service providers, particularly for academic customers who might otherwise use Oxford StemTech.

Others

• Stemcell Technologies: Major supplier of cell culture media, reagents, and primary cell products supporting iPSC and stem cell research. Not a direct service competitor but an enabling supplier whose products are used in iPSC workflows alongside Oxford StemTech's services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/oxford-stemtech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford StemTech